Effect of fluticasone proprionate 0.05% cream on narrow band UV-B phototherapy in active vitiligo: a randomised single blinded controlled trial
- Conditions
- vitiligowhite spot disease10035023
- Registration Number
- NL-OMON33795
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 70
Patients with active vitiligo, eligible for NB-UVB phototherapy;
Subjects attending the outpatient department of the SNIP;
Adult patients: * 18 years;
Subject is willing and able to give written informed consent.
With a personal or a family history of skin cancer (non-melanoma skin cancer: first degree family members, melanoma: any family member)
With a personal history of photosensitivity and/or phototoxicity disorders
With skin type I (according to Fitzpatrick classification I-VI)
Who are pregnant
Who are taking medications known to cause photosensitivity and/or phototoxicity and chronic or very frequent use of any medication that can influence the UVB response (eg. tetracycline, retinoids, sulfonamids, psoralens, NSAID*s)
With other skin diseases that would impair evaluation of repigmentation, such as psoriasis and eczema.
Who are not able to have 2 times weekly NB-UVB phototherapy
With local immunosuppressive treatment or 6 weeks prior to enrolment. For these patients a washout period of 6 weeks will be required.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The onset and degree of pigment spread is assessed by digital image analysis,<br /><br>and the patients and doctors satisfaction will be evaluated</p><br>
- Secondary Outcome Measures
Name Time Method <p>-</p><br>